Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PM2
The NM_001142276.2(APLP2):c.106G>T(p.Ala36Ser) variant causes a missense, splice region change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. 2/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Uncertain significance (★).
APLP2 (HGNC:598): (amyloid beta precursor like protein 2) This gene encodes amyloid precursor- like protein 2 (APLP2), which is a member of the APP (amyloid precursor protein) family including APP, APLP1 and APLP2. This protein is ubiquitously expressed. It contains heparin-, copper- and zinc- binding domains at the N-terminus, BPTI/Kunitz inhibitor and E2 domains in the middle region, and transmembrane and intracellular domains at the C-terminus. This protein interacts with major histocompatibility complex (MHC) class I molecules. The synergy of this protein and the APP is required to mediate neuromuscular transmission, spatial learning and synaptic plasticity. This protein has been implicated in the pathogenesis of Alzheimer's disease. Multiple alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Aug 2011]
Review Status: criteria provided, single submitter
Collection Method: clinical testing
The c.106G>T (p.A36S) alteration is located in exon 2 (coding exon 2) of the APLP2 gene. This alteration results from a G to T substitution at nucleotide position 106, causing the alanine (A) at amino acid position 36 to be replaced by a serine (S). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -
Gain of glycosylation at A36 (P = 0.0306);.;.;Gain of glycosylation at A36 (P = 0.0306);Gain of glycosylation at A36 (P = 0.0306);Gain of glycosylation at A36 (P = 0.0306);Gain of glycosylation at A36 (P = 0.0306);.;